Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Safety study of tanezumab in relief of osteoarthritis pain This study was terminated on 6 December 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Osteoarthritis of the knee or hip based on American College of Rheumatology criteria with a radiographic (X ray) confirmation (a Kellgren Lawrence x-ray grade of ≥2);
You may not be if
Body mass index (BMI) of \>39 kg/m2;
Pregnancy or intent to become pregnant
Planned surgical procedure during the duration of the study
History of clinically significant cardiovascular, central nervous system or psychiatric disease
Previous exposure to exogenous NGF or to an anti NGF antibody;
Use of biologics other than study medication, Live or live-attenuated intranasal vaccines (eg, Flumist), are allowable exceptions
